Asia300

Dr. Reddy's Laboratories Ltd.

India

  • 1m
  • 3m
  • 6m
  • 1y
  • 2y
  • 5y
Aug 18, 2017
Prev close: 1,982.9
Aug 18, 2017
Market cap:
Market cap(USD):
328,677.18M
5,125.77M
Shares: 165.75M

Currency in INR

Company profile

Market(Ticker): BOM(500124)
Sector:
Industry:
Health Technology
Pharmaceuticals: Generic
Full time employees: 22,671

Business summary

Dr. Reddy's Laboratories Ltd. engages in the manufacturing and marketing of pharmaceutical products. It operates through the following segments: Pharmaceutical Services and Active Ingredient, Global Generics and Proprietary Products. The Pharmaceutical Services and Active Ingredients segments include active pharmaceutical ingredients and intermediaries also known as active pharmaceutical products or bulk drug; it also provides research services. The Global Generics segment consists of finished pharmaceutical products ready for consumption. The Proprietary Products segment involves the discovery of new chemical entities for subsequent commercialization and out-licensing. The company was founded by Kallam Anji Reddy on February 24, 1984 and is headquartered in Hyderabad, India.

Company background

Dr. Reddy's Laboratories is a leading Indian generic drugmaker that operates business in more than 20 countries. Founder K. Anji Reddy is among the business leaders who spearheaded the development of India's generic drug industry.

The company was founded in 1984, and its generic drug business found its way to a growth track in 1986. It continues to steadily expand in 2000s. It has made acquisitions and now has development bases in the U.K. and the Netherlands.

Dr. Reddy's Laboratories has been stepping up its biomedicine operations. These include the development of anti-cancer drugs, which the company considers a big source of future earnings. Dr. Reddy's Laboratories aims to reinforce its biomedicine operations through a tie-up with the German drugmaker Merck.

Anji Reddy died in 2013. His son, Satish Reddy, serves as company chairman and his son-in-law as co-chairman. The founding family owns nearly 25% of the company's shares.

In the news

Financial highlights

Mar 2017

  • Local currency
  • US Dollar
Revenue 140,809M
Gross profit 73,531M
Operating income 12,878M
Income before tax 14,304M
Net income 12,039M
EBITDA 24,155M
Diluted EPS 72.09
Dividends per share 20
Total assets 219,821M
Total liabilities 95,777M
Total equity 124,044M
Operating cash flow 21,216M

Currency in INR

Revenue 2,099.83M
Gross profit 1,096.54M
Operating income 192.04M
Income before tax 213.31M
Net income 179.53M
EBITDA 360.21M
Diluted EPS 1.07
Dividends per share 0.29
Total assets 3,385.24M
Total liabilities 1,474.96M
Total equity 1,910.27M
Operating cash flow 316.38M

Currency in USD

Valuation measures

Mar 2017

PER 36.44
ROA 5.63%
ROE 9.54%
Operating margin 9.14%
Profit margin 8.54%

Key executive

  • Co-Chairman, Chief Executive Officer & MD: Gunupati Venkateswara Prasad
  • President, CFO & Global Head-IT: Saumen Chakraborty
  • Chief Operating Officer: Abhijit Mukherjee
  • Secretary & Compliance Officer: Sandeep Poddar
  • EVP, Head-Emerging Markets & Global Generics: M. V. Ramana

Share holders

  • Dr. Reddy's Holdings Ltd.(24.5%)
  • First State Investment Management (UK) Ltd.(6.6%)
  • OppenheimerFunds, Inc.(5.2%)
  • BlackRock Fund Advisors(2.0%)
  • Franklin Templeton Asset Management (India) Pvt Ltd.(1.8%)
  • Franklin Advisers, Inc.(1.3%)
  • The Vanguard Group, Inc.(1.0%)
  • Reliance Nippon Life Asset Management Ltd.(0.9%)
  • PRASAD GUNUPATI VENKATESWARA(0.8%)
  • REDDY SATISH KALLAM(0.7%)

Address

  • Website: http://www.drreddys.com
  • Address: Door No. 8-2-337, Road No. 3, Hyderabad, 500034, India
  • Phone: +91.40.49002900

Copyright © 2017 FactSet Research Systems Inc. All rights reserved.